Eye fluid study aims to uncover why some macular degeneration patients Don't respond to treatment
NCT ID NCT03630562
First seen Mar 30, 2026 · Last updated Jun 17, 2026 · Updated 14 times
Summary
This study looked at 100 people with wet age-related macular degeneration (AMD) to measure certain proteins in their eye fluid. The goal was to understand why about 37% of patients do not respond well to standard anti-VEGF injections. By measuring these proteins, researchers hope to find clues that could predict treatment response in the future.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Pasteur 2 - Service d'Ophtalmologie
Nice, 06001, France
Conditions
Explore the condition pages connected to this study.